Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?

DSpace/Manakin Repository

Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?
 
Chan, Chilam; Lustig, Marta; Baumann, Niklas; Valerius, Thomas; van Tetering, Geert; Leusen, Jeanette H.W.
(2022) Frontiers in Immunology, volume 13, pp. 1 - 2
(Comment)
Abstract
A Corrigendum onTargeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies? by Chan C, Lustig M, Baumann N, Valerius T, van Tetering G and Leusen JHW (2022) 13:932155. doi: 10.3389/fimmu.2022.932155
Download/Full Text
Open Access version via Utrecht University Repository Publisher version
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: antibodies, cancer immonotherapy, CD47-SIRPalpha axis, IgA, immune checkpoint, macrophages, myeloid checkpoints, neutrophils (PMNs), Immunology and Allergy, Immunology, Published Erratum
DOI: https://doi.org/10.3389/fimmu.2022.1017924
ISSN: 1664-3224
Publisher: Frontiers Media S. A.
Note: Publisher Copyright: Copyright © 2022, Chan, Lustig, Baumann, Valerius, van Tetering and Leusen.
(Peer reviewed)